Methods of treating tuberous sclerosis complex with cannabidiol and everolimus

A method of initiating everolimus treatment in a human who is suffering from tuberous sclerosis complex and has partial onset seizures who is currently being treated with a therapeutically effective amount of cannabidiol, the method comprising:

• (a) co-administering a reduced starting dose of everolimus and the therapeutically effective amount of cannabidiol to the human;
• (b) monitoring the human's blood plasma concentration of everolimus;
• (c) increasing the reduced starting dose of everolimus administered in step (a) by at least 10% to a dose that achieves a blood plasma trough concentration of everolimus ranging from 5-15 ng/mL, Cmax of everolimus that is less than or equal to 50 ng/mL, or AUC0-24 of everolimus that is less than or equal to 500 h*ng/mL;
• wherein said monitoring in step (b) occurs one to two weeks after the human begins receiving everolimus;
• wherein cannabidiol is synthetic or purified;
• and
• wherein the starting dose of everolimus for treating tuberous sclerosis complex in the human is 5 mg/m2 once daily.